Participated · Series D · Jun 2025

Beewise develops the BeeHome™, an AI-driven, solar-powered robotic beehive that enables real-time autonomous treatment and remote management by beekeepers and growers. The company’s BeeHome™ 4 includes Heat Chamber Technology that eliminates 99% of lethal Varroa mites without chemicals. Beewise says all 1,240 BeeHomes currently in operation use machine learning to continuously monitor hive health, and the company reports pollinating 300K+ acres annually for hundreds of growers. Its system combines precision robotics, proprietary software, and machine learning (RNNs, reinforcement learning) to deliver active interventions rather than passive monitoring. Beewise positions the product as a climate adaptation solution to address extreme weather, pesticides, and pathogen threats to bees. The company plans to use new capital to accelerate technological innovation, market expansion, and research in service of its mission to save bees and secure the global food supply. Beewise, founded in 2018, produces the Beehome: a solar-powered automated apiary enclosure that monitors beehives and provides climate control, feeding, and automated harvesting. The company sells the product to farmers on a RaaS model—$400 monthly plus a $2,000 delivery/setup fee—for 24 colonies with ongoing maintenance. The system monitors for issues (including intrusive animals) and adjusts conditions to prevent swarming, aiming to improve yields and pollination and support bee population recovery. Beewise recently unveiled a new Beehome that is 32% smaller and 20% lighter than its predecessor, with faster harvesting and improved feeding and heating. The firm reports thousands of orders placed in the U.S. in the last few months and plans to increase manufacturing and develop additional product iterations. Beewise has raised over $120 million to date, including a recent $80 million Series C to help meet market demand and scale operations. Beewise develops Beehome, a retrofitted shipping-container system that houses ~40 colonies (about 2 million bees) and uses computer vision, robotic arms, sensors, and software to monitor, treat, and harvest hives. Its ML models (trained on thousands of images) detect pests such as varroa mites and a decision-making AI on an Nvidia Jetson platform can quarantine affected hives, control climate, apply targeted treatments, and automatically extract honey. Beehome also detects swarm risk and sends actionable alerts to beekeepers via an iPad app. The product is currently in beta, priced at $15 per hive per month, and Beewise reports a 15-person team with over 40 customers. The company aims to ramp production and contract manufacturers to deliver hundreds to thousands of devices per year, targeting a global market it estimates at 100 million hives (~$14.4B opportunity).

Led · Equity · Feb 2025

Stratasys is an additive manufacturing company based in Tel Aviv that specializes in polymer 3D printing solutions. Its core offerings include connected 3D printers, polymer materials, a software ecosystem, and parts-on-demand. The company serves industries such as aerospace, automotive, consumer products and healthcare, and its solutions are positioned to deliver competitive advantages across the product value chain. Led by CEO Dr. Yoav Zeif, Stratasys said it will use the new capital to enhance shareholder value and support continued execution of its growth strategy. The company also plans to use the funds to further strengthen its balance sheet. The article does not disclose operating metrics or other financial details.

Led · Series D · Jul 2024

Scopio Labs has launched an AI-based Complete Blood Morphology (CBM) analyzer designed to fully automate blood morphology diagnostics. The CBM uses Scopio’s Full-Field technology, combining advanced imaging and AI to analyze ten times more cells than current methods. The product targets the global laboratory staffing crisis by standardizing and automating peripheral blood smear (PBS) reviews and potentially eliminating routine human reviews. Scopio holds CE-marked and FDA-cleared digital imaging applications and plans to showcase the CBM at the ADLM 2025 Annual Conference. Viola Growth invested an additional $10 million to support the CBM’s market launch, raising Scopio’s Series D to $52 million. Company leadership says the technology could reshape hematology workflows, economics, and enable development of morphology-based biomarkers for earlier detection and monitoring of disease. Scopio Labs develops Full-Field Digital Cell Morphology imaging and analysis platforms that use computational photography to capture high-resolution images of thousands of cells. Its platform pairs full-field imaging with clinical AI-based decision support to improve workflow efficiency, enable remote consultation, and expedite diagnostic decision-making in blood cell analysis. The technology is intended to supplant manual microscopy by providing a full-field view of all regions of clinical interest at high resolution. Scopio says it will use new capital to accelerate market penetration, scale sales and marketing, and strengthen customer support globally. The company also plans continued development of its digital morphology platform and creation of next-generation products for hematology laboratories and hospitals. Financially, Scopio recently closed a $42 million Series D, bringing its total fundraising to $130 million. Scopio Labs develops a digital microscopy platform that captures and digitizes full-slide microscopy data using advanced computational photography to reconstruct high-resolution images. Its automated scanning systems deliver high-quality images and include computer-vision based decision support for hematology, pathology, research and veterinary use. The company has launched ScopioVet, an end-to-end digital cytology solution for veterinary professionals. Scopio recently received CE mark certification for its X100 Full Field Peripheral Blood Smear (PBS) system, an all-in-one automated in-vitro hematology diagnostic platform that enables remote consultation. A multi-center study in preparation for an FDA submission is being completed. Led by co-founder and CEO Itai Hayut, the company plans to expand commercial operations across the United States and Europe, ramp up manufacturing and sales, and build a stronger clinical trial pipeline to broaden its offerings. Scopio Labs develops next-generation digital microscopes based on computational imaging breakthroughs and a suite of dedicated image analysis tools. Its technology targets clinical and research applications including cancer, hematology, cytology, academic research and drug discovery. The company was founded in 2015 by Itai Hayut and Erez Na’aman. Scopio plans to use the new funding to expand its Tel Aviv–based team and is hiring computer vision experts, physicists and software developers. The article frames the company as enabling dramatic clinical and research improvements and powering further innovation in diagnostics and discovery.

Led · Series B · Apr 2024

Velox, based in Kfar Saba, Israel, develops, manufactures and sells industrial-grade direct-to-shape digital decoration solutions for the rigid container industry. Its proprietary technology, based on formulated inks and a dedicated deposition architecture, introduces an entirely new approach to digital printing for packaging decoration. Velox's commercial solutions include industrial-grade digital decorators for mass production of beverage cans, tubes, and aerosol cans. The company is led by Marian Cofler (CEO) and Adrian Cofler (COO). Velox raised $38M in funding led by Fortissimo Capital with participation from existing investors including JAL Ventures, O.R.T. Technologies, Ilan Holdings, Evonik, Waypoint Investors and Migdal Insurance & Finance. The company intends to use the funds to accelerate its global presence and to innovate in high-speed, direct-to-container digital printing. Velox develops and manufactures industrial-grade direct-to-shape digital decoration solutions for the rigid container industry using its proprietary DTS-Inkjet technology. The DTS-Inkjet system is based on formulated inks and a deposition architecture designed to match or replace existing decoration technologies on quality, production speed, and total cost-of-ownership. The company positions its solution as an end-to-end replacement that also offers greater agility and efficiency versus legacy methods. Velox was co-founded by Marian Cofler (CEO) and Adrian Cofler (COO). The business completed a $32m funding round to support commercialization and scale. Velox intends to use the proceeds to expand digital printing from special editions into the mass packaging decoration market.

Participated · Equity · Dec 2022

Equinom uses its Manna™ technology platform and a large seed vault to breed higher-quality, non-GMO source crops (including pea and soy) optimized for food applications that require minimal processing. Its optimized crops aim to improve taste, nutrition, and reduce cost and complexity for plant-based foods, enabling food companies to deliver tastier and more affordable alternatives to meat and dairy. Equinom plans to commercialize these plant-protein ingredients through established multinational ingredient suppliers and expand seed development and grain production for ultra-high protein soy and pea varieties. The company also intends to invest in R&D and breeding programs for additional crops including chickpea, fava, mung bean, and cowpea, and to add key personnel. Financially, Equinom announced a $35 million tranche of funding and has raised over $71 million in total to date. The company presented this news from Indianapolis. Equinom develops seeds for plant-based proteins using AI-driven technology, a distinct methodology, and a proprietary genomic database to breed improved traits such as protein amount and functionality, flavor, yield, and field performance. The company begins with exotic and ancient crop types and applies non-GMO breeding methods to reverse years of yield-focused breeding that it says reduced ingredient quality. Its sesame seeds are grown on over 100,000 acres across five continents, and Equinom says it has secured 'millions of dollars in contracts' with market-leading food brands for custom-designed ingredients. Improved seeds for pea, soy, and other legumes are slated to debut in October this year. Equinom has collaborated with Sabra, PepsiCo, and Roquette and positions itself as a 'sophisticated ingredient company' targeting food manufacturers seeking lower-cost, cleaner-label plant-based inputs. The company will use new funding to boost sales and marketing and to expand R&D. Equinom is a Kibbutz Givat Brenner, Israel-based seed-breeding company led by CEO Gil Shalev that builds an ecosystem connecting food companies to the supply chain to improve transparency and responsible sourcing of plant protein. The company develops mechanically harvestable seed varieties and has become a preferred supplier for sesame seeds. Equinom plans to launch a high-protein pea variety in 2021. The firm closed a $10M Series B to support its growth. It intends to use the funds to accelerate global expansion and to build talent and infrastructure. The description and plans are focused on supplying high-value plant-protein ingredients to food companies. Equinom develops proprietary software, algorithms and data‑science methods to identify genomic regions controlling complex, multi‑gene crop traits and to select optimal combinations for cross‑breeding. The company deliberately avoids genetic modification and gene editing, positioning its products for a global clean‑label market. Equinom both builds the technology stack and runs breeding programs, selling seed and collecting royalties as a primary revenue stream. Its first commercialized crop is sesame, bred for mechanical harvestability and higher yield; the company targets capturing 5–10% of the $8 billion sesame market. Equinom is now focusing on legumes, starting with peas, aiming to commercialize varieties with 35%–55% higher protein content and improved protein quality by 2021. The company was founded in 2012 and is headquartered in Israel; it is building a gene bank/database to improve discovery across species via machine learning. EQUInom is an Israeli seed‑breeding startup that uses computational breeding technology to create seeds for the global food industry. The company applies genomics, bioinformatics, and phenomics in its proprietary breeding platform. It plans to use the new capital to boost its plant‑protein seed breeding program. The $1.25M round was led by Hazera, a field crops and seed production specialist group. EQUInom has signed with Obela, the joint venture of PepsiCo and Strauss Group, to participate in a breeding program using its proprietary technology. Recent market research cited in the article notes the plant‑protein market totaled $7.7 billion last year and could reach $10 billion by 2020, indicating growing demand for protein‑rich crops. The funding round brings the company’s total financing to $2.25M.